These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 20357366)

  • 21. PYY3-36 injection in mice produces an acute anorexigenic effect followed by a delayed orexigenic effect not observed with other anorexigenic gut hormones.
    Parkinson JR; Dhillo WS; Small CJ; Chaudhri OB; Bewick GA; Pritchard I; Moore S; Ghatei MA; Bloom SR
    Am J Physiol Endocrinol Metab; 2008 Apr; 294(4):E698-708. PubMed ID: 18285527
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The therapeutic potential of gut hormone peptide YY3-36 in the treatment of obesity.
    Small CJ; Bloom SR
    Expert Opin Investig Drugs; 2005 May; 14(5):647-53. PubMed ID: 15926870
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of PYY1-36 and PYY3-36 on appetite, energy intake, energy expenditure, glucose and fat metabolism in obese and lean subjects.
    Sloth B; Holst JJ; Flint A; Gregersen NT; Astrup A
    Am J Physiol Endocrinol Metab; 2007 Apr; 292(4):E1062-8. PubMed ID: 17148749
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of peptide YY3-36 on food intake in humans.
    Degen L; Oesch S; Casanova M; Graf S; Ketterer S; Drewe J; Beglinger C
    Gastroenterology; 2005 Nov; 129(5):1430-6. PubMed ID: 16285944
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of food intake in obese subjects by peptide YY3-36.
    Batterham RL; Cohen MA; Ellis SM; Le Roux CW; Withers DJ; Frost GS; Ghatei MA; Bloom SR
    N Engl J Med; 2003 Sep; 349(10):941-8. PubMed ID: 12954742
    [TBL] [Abstract][Full Text] [Related]  

  • 26. L-arginine promotes gut hormone release and reduces food intake in rodents.
    Alamshah A; McGavigan AK; Spreckley E; Kinsey-Jones JS; Amin A; Tough IR; O'Hara HC; Moolla A; Banks K; France R; Hyberg G; Norton M; Cheong W; Lehmann A; Bloom SR; Cox HM; Murphy KG
    Diabetes Obes Metab; 2016 May; 18(5):508-18. PubMed ID: 26863991
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial.
    Wynne K; Park AJ; Small CJ; Meeran K; Ghatei MA; Frost GS; Bloom SR
    Int J Obes (Lond); 2006 Dec; 30(12):1729-36. PubMed ID: 16619056
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bifidobacterium as an oral delivery carrier of oxyntomodulin for obesity therapy: inhibitory effects on food intake and body weight in overweight mice.
    Long RT; Zeng WS; Chen LY; Guo J; Lin YZ; Huang QS; Luo SQ
    Int J Obes (Lond); 2010 Apr; 34(4):712-9. PubMed ID: 20065960
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial.
    Wynne K; Park AJ; Small CJ; Patterson M; Ellis SM; Murphy KG; Wren AM; Frost GS; Meeran K; Ghatei MA; Bloom SR
    Diabetes; 2005 Aug; 54(8):2390-5. PubMed ID: 16046306
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gastrointestinal satiety signals III. Glucagon-like peptide 1, oxyntomodulin, peptide YY, and pancreatic polypeptide.
    Stanley S; Wynne K; Bloom S
    Am J Physiol Gastrointest Liver Physiol; 2004 May; 286(5):G693-7. PubMed ID: 15068960
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of alginate on satiation, appetite, gastric function, and selected gut satiety hormones in overweight and obesity.
    Odunsi ST; Vázquez-Roque MI; Camilleri M; Papathanasopoulos A; Clark MM; Wodrich L; Lempke M; McKinzie S; Ryks M; Burton D; Zinsmeister AR
    Obesity (Silver Spring); 2010 Aug; 18(8):1579-84. PubMed ID: 19960001
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Physiological and pathophysiological aspects of incretin hormones and glucagon.
    Bagger JI
    Dan Med J; 2017 Jan; 64(1):. PubMed ID: 28007055
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Native Oxyntomodulin Has Significant Glucoregulatory Effects Independent of Weight Loss in Obese Humans With and Without Type 2 Diabetes.
    Shankar SS; Shankar RR; Mixson LA; Miller DL; Pramanik B; O'Dowd AK; Williams DM; Frederick CB; Beals CR; Stoch SA; Steinberg HO; Kelley DE
    Diabetes; 2018 Jun; 67(6):1105-1112. PubMed ID: 29545266
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Supraphysiological doses of intravenous PYY3-36 cause nausea, but no additional reduction in food intake.
    le Roux CW; Borg CM; Murphy KG; Vincent RP; Ghatei MA; Bloom SR
    Ann Clin Biochem; 2008 Jan; 45(Pt 1):93-5. PubMed ID: 18275682
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of active commuting and leisure-time exercise on appetite in individuals with overweight and obesity.
    Quist JS; Blond MB; Gram AS; Steenholt CB; Janus C; Holst JJ; Rehfeld JF; Sjödin A; Stallknecht B; Rosenkilde M
    J Appl Physiol (1985); 2019 Apr; 126(4):941-951. PubMed ID: 30605397
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice.
    Talsania T; Anini Y; Siu S; Drucker DJ; Brubaker PL
    Endocrinology; 2005 Sep; 146(9):3748-56. PubMed ID: 15932924
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potent antiobesity effect of a short-length peptide YY-analogue continuously administered in mice.
    Nishizawa N; Niida A; Adachi Y; Masuda Y; Kumano S; Yokoyama K; Asakawa T; Hirabayashi H; Amano N; Takekawa S; Ohtaki T; Asami T
    Bioorg Med Chem Lett; 2017 Aug; 27(16):3829-3832. PubMed ID: 28684122
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of the postprandial release of peptide YY and proglucagon-derived peptides in the rat.
    Anini Y; Fu-Cheng X; Cuber JC; Kervran A; Chariot J; Roz C
    Pflugers Arch; 1999 Aug; 438(3):299-306. PubMed ID: 10398859
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of different intermittent peptide YY (3-36) dosing strategies on food intake, body weight, and adiposity in diet-induced obese rats.
    Reidelberger RD; Haver AC; Chelikani PK; Buescher JL
    Am J Physiol Regul Integr Comp Physiol; 2008 Aug; 295(2):R449-58. PubMed ID: 18550871
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ghrelin suppresses cholecystokinin (CCK), peptide YY (PYY) and glucagon-like peptide-1 (GLP-1) in the intestine, and attenuates the anorectic effects of CCK, PYY and GLP-1 in goldfish (Carassius auratus).
    Blanco AM; Bertucci JI; Valenciano AI; Delgado MJ; Unniappan S
    Horm Behav; 2017 Jul; 93():62-71. PubMed ID: 28506816
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.